vs
Dominari Holdings Inc.（DOMH）与Strata Critical Medical, Inc.（SRTA）财务数据对比。点击上方公司名可切换其他公司
Dominari Holdings Inc.的季度营收约是Strata Critical Medical, Inc.的1.3倍（$30.1M vs $22.7M），Strata Critical Medical, Inc.同比增速更快（361.2% vs 220.4%），过去两年Dominari Holdings Inc.的营收复合增速更高（369.1% vs -33.6%）
Strata Critical Medical, Inc.是一家医疗技术企业，设计、生产及销售用于重症监护、麻醉及外科场景的一次性医疗用品，主要服务北美及部分欧洲地区的医疗机构，专注提升患者安全与临床诊疗效率。
DOMH vs SRTA — 直观对比
营收规模更大
DOMH
是对方的1.3倍
$22.7M
营收增速更快
SRTA
高出140.8%
220.4%
两年增速更快
DOMH
近两年复合增速
-33.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.1M | $22.7M |
| 净利润 | $-131.8M | — |
| 毛利率 | — | -0.9% |
| 营业利润率 | -8.9% | -18.4% |
| 净利率 | -438.1% | — |
| 营收同比 | 220.4% | 361.2% |
| 净利润同比 | -12426.2% | — |
| 每股收益（稀释后） | $-6.94 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOMHSRTA
| Q4 25 | $30.1M | $22.7M | ||
| Q3 25 | $50.8M | $49.3M | ||
| Q2 25 | $34.1M | $70.8M | ||
| Q1 25 | $8.1M | $54.3M | ||
| Q4 24 | $9.4M | $-8.7M | ||
| Q3 24 | $4.0M | $36.1M | ||
| Q2 24 | $6.2M | $67.9M | ||
| Q1 24 | $1.4M | $51.5M |
净利润DOMHSRTA
| Q4 25 | $-131.8M | — | ||
| Q3 25 | $125.2M | $57.4M | ||
| Q2 25 | $16.6M | $-3.7M | ||
| Q1 25 | $-32.5M | $-3.5M | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $-4.2M | $-2.0M | ||
| Q2 24 | $-6.1M | $-11.3M | ||
| Q1 24 | $-5.4M | $-4.2M |
毛利率DOMHSRTA
| Q4 25 | — | -0.9% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 25.1% | ||
| Q1 25 | — | 22.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 24.1% | ||
| Q1 24 | — | 19.7% |
营业利润率DOMHSRTA
| Q4 25 | -8.9% | -18.4% | ||
| Q3 25 | -3.1% | -11.4% | ||
| Q2 25 | -57.0% | -7.0% | ||
| Q1 25 | -394.6% | -14.0% | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | -79.1% | -19.7% | ||
| Q2 24 | -44.3% | -17.9% | ||
| Q1 24 | -205.2% | -19.2% |
净利率DOMHSRTA
| Q4 25 | -438.1% | — | ||
| Q3 25 | 246.4% | 116.5% | ||
| Q2 25 | 48.7% | -5.3% | ||
| Q1 25 | -400.5% | -6.4% | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | -104.2% | -5.4% | ||
| Q2 24 | -99.1% | -16.7% | ||
| Q1 24 | -398.0% | -8.2% |
每股收益（稀释后）DOMHSRTA
| Q4 25 | $-6.94 | $-0.11 | ||
| Q3 25 | $7.27 | $0.70 | ||
| Q2 25 | $1.12 | $-0.05 | ||
| Q1 25 | $-3.02 | $-0.04 | ||
| Q4 24 | $0.21 | $-0.11 | ||
| Q3 24 | $-0.67 | $-0.03 | ||
| Q2 24 | $-1.01 | $-0.15 | ||
| Q1 24 | $-0.91 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.5M | $31.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $69.4M | $279.1M |
| 总资产 | $112.9M | $325.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOMHSRTA
| Q4 25 | $80.5M | $31.0M | ||
| Q3 25 | $176.2M | $22.8M | ||
| Q2 25 | $28.2M | $58.8M | ||
| Q1 25 | $18.9M | $34.8M | ||
| Q4 24 | $8.2M | $18.4M | ||
| Q3 24 | $7.2M | $20.0M | ||
| Q2 24 | $12.1M | $26.3M | ||
| Q1 24 | $7.1M | $36.8M |
股东权益DOMHSRTA
| Q4 25 | $69.4M | $279.1M | ||
| Q3 25 | $210.2M | $283.0M | ||
| Q2 25 | $88.6M | $223.1M | ||
| Q1 25 | $42.4M | $219.7M | ||
| Q4 24 | $39.9M | $221.9M | ||
| Q3 24 | $38.3M | $233.5M | ||
| Q2 24 | $42.4M | $229.4M | ||
| Q1 24 | $47.7M | $236.6M |
总资产DOMHSRTA
| Q4 25 | $112.9M | $325.5M | ||
| Q3 25 | $223.4M | $335.1M | ||
| Q2 25 | $109.3M | $257.9M | ||
| Q1 25 | $52.3M | $250.6M | ||
| Q4 24 | $47.1M | $256.7M | ||
| Q3 24 | $43.4M | $282.9M | ||
| Q2 24 | $49.1M | $280.3M | ||
| Q1 24 | $52.2M | $282.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.7M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-10.2M |
| 自由现金流率自由现金流/营收 | — | -44.7% |
| 资本支出强度资本支出/营收 | — | 8.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-58.5M |
8季度趋势，按日历期对齐
经营现金流DOMHSRTA
| Q4 25 | $22.7M | $-8.3M | ||
| Q3 25 | $-4.9M | $-37.3M | ||
| Q2 25 | $-353.0K | $-3.1M | ||
| Q1 25 | $1.2M | $-246.0K | ||
| Q4 24 | $-16.7M | $-1.8M | ||
| Q3 24 | $-4.7M | $6.4M | ||
| Q2 24 | $1.4M | $8.4M | ||
| Q1 24 | $-8.6M | $-15.6M |
自由现金流DOMHSRTA
| Q4 25 | — | $-10.2M | ||
| Q3 25 | — | $-40.1M | ||
| Q2 25 | — | $-5.4M | ||
| Q1 25 | — | $-2.9M | ||
| Q4 24 | — | $-6.3M | ||
| Q3 24 | — | $-3.0M | ||
| Q2 24 | — | $-7.7M | ||
| Q1 24 | — | $-16.4M |
自由现金流率DOMHSRTA
| Q4 25 | — | -44.7% | ||
| Q3 25 | — | -81.4% | ||
| Q2 25 | — | -7.6% | ||
| Q1 25 | — | -5.3% | ||
| Q4 24 | — | 72.7% | ||
| Q3 24 | — | -8.2% | ||
| Q2 24 | — | -11.4% | ||
| Q1 24 | — | -31.8% |
资本支出强度DOMHSRTA
| Q4 25 | — | 8.1% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | -52.6% | ||
| Q3 24 | — | 25.8% | ||
| Q2 24 | — | 23.8% | ||
| Q1 24 | — | 1.6% |
现金转化率DOMHSRTA
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | -0.65× | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
